First Niagara Bank’s iShares Biotechnology ETF IBB Stock Holding History

First Niagara Bank’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$302K	Buy	+3,525	New	+$316K	0.09%	152

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Societe Generale $14.1B AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Niagara Bank's IBB Position: Q2 2016 in Review

First Niagara Bank opened a new position in iShares Biotechnology ETF (IBB) in Q2 2016: 3,525 shares worth $302K. The stake represents 0.09% of the portfolio and ranks #152 among its holdings.

429 funds tracked by Wall St. Rank hold IBB as of Q2 2016.

First Niagara Bank held 3,525 shares of iShares Biotechnology ETF worth $302K as of Q2 2016.
iShares Biotechnology ETF was a new First Niagara Bank position in Q2 2016.
iShares Biotechnology ETF made up 0.09% of First Niagara Bank's portfolio in Q2 2016, its #152 holding.
429 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2016.

Based on First Niagara Bank's 13F filing for Q2 2016, filed 25 Jul 2016.